Cell Wall Synthesis Inhibition (null)

"Cell Wall Synthesis Inhibition" refers to the therapeutic strategy and drug target class that disrupts the assembly of the bacterial cell wall, primarily the peptidoglycan scaffold. Drugs acting through this mechanism selectively kill or inhibit bacteria by targeting enzymes or substrates involved in cell wall biosynthesis, such as penicillin-binding proteins (PBPs), transglycosylases, and MurA. This mechanism is highly effective due to the absence of peptidoglycan in mammalian cells, enhancing selective toxicity. The most clinically significant drug classes include β-lactams and glycopeptides. Resistance may arise via mutational changes in target enzymes, the acquisition of alternative pathways, or enzymatic drug degradation[2][3][7][9].

Other names

Inhibition of cell wall biosynthesisCell wall synthesis inhibitors (as a drug class)Peptidoglycan synthesis inhibition

Inhibiting peptidoglycan synthesis; Blocking cross-linking of the cell wall (e.g., β-lactams binding PBPs); Preventing precursor formation (e.g., fosfomycin inhibiting MurA, cycloserine inhibiting alanine racemase and D-Ala-D-Ala ligase); Disrupting lipid II assembly (glycopeptides, lantibiotics)